Development of a Rationally Attenuated Live Vaccine for Francisella tularensis

土拉弗朗西斯菌合理减毒活疫苗的研制

基本信息

  • 批准号:
    8511015
  • 负责人:
  • 金额:
    $ 19.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-04-10 至 2015-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Francisella tularensis (Ft) is a Gram negative, intracellular (macrophage-tropic) bacterium, and the etiologic agent of tularemia. Ft is classified as a Category A agent because it may can be contracted with low inocula by the respiratory route and causes rapid morbidity and mortality if untreated both mice and humans. Ft Live Vaccine Strain (LVS), a type B strain derived from Ft subsp. holarctica, is attenuated for man, but causes a tularemia-like disease in mice when administered intranasally or intraperitoneally. Although Ft LVS was shown to reduce the incidence of laboratory-acquired respiratory tularemia, it is not licensed in the USA because the molecular basis for its attenuation has not been fully elucidated, the strain exhibits phenotypic inconsistencies, and Ft LVS immunization fails to provide complete protection against some subspecies of Ft. Therefore, additional prophylactic products and/or attenuated vaccine strains must be developed for use against possible bioterrorism threats. Our recently published results show that insertional inactivation of the lpxF gene in F. novicida (Fn) resulted in an attenuated strain with an altered lipopolysaccharide (LPS) structure that protected immunized mice against >25,000 LD50 challenge with wild-type (WT) Fn. We now show that a similar mutation in Ft LVS resulted in the same structural modification to the lipid A and was avirulent at >106 LD50 after subcutaneous infection of C57BL/6 and BALB/c mice. The goal of this revised R21 proposal is to develop live, rationally attenuated Ft vaccines based on unmarked deletion of lpxF in both Ft LVS (Type B) and Ft Schu S4 (Type A) strains. After engineering an unmarked lpxF deletion in these two strains, we will confirm the structure of the lipid A from each mutant by mass spectroscopy, and confirm that each mutant is, indeed, attenuated in mice. Additionally, we will test their capacity to protect WT, IFN-r-/-, and TLR2-/- mice against homologous and heterologous challenge. Finally, we will test for the capacity of each mutant strain to induce macrophage gene expression associated with "classically activated" (microbicidal) vs. "alternatively activated" (shown previously to facilitate intracytosolic replication) macrophages and for the ability to replicate intracellularly in vitro. At the completion of this study, we expect to have developed a rationally attenuated vaccine candidate that will protect against multiple Ft Type A and Type B Francisella strains.
描述(由申请方提供):土拉热弗朗西丝菌(Ft)是一种革兰氏阴性细胞内(嗜巨噬细胞)细菌,是土拉菌病的病原体。Ft是机密 作为A类病原体,因为它可以通过呼吸道途径在低接种量下感染,如果不治疗,小鼠和人都会迅速发病和死亡。Ft活疫苗株(LVS),一种来源于Ft亚种的B型毒株。holarctica对人是减毒的,但当鼻内或腹膜内给药时在小鼠中引起兔热病样疾病。尽管Ft LVS显示可降低实验室获得性呼吸道土拉菌病的发生率,但由于其减毒的分子基础尚未完全阐明,菌株表现出表型不一致性,并且Ft LVS免疫接种未能提供针对Ft某些亚种的完全保护,因此在美国未获得许可。因此,必须开发额外的预防性产品和/或减毒疫苗株以用于对抗可能的生物恐怖主义威胁。我们最近发表的结果表明,插入失活的 lpxF基因在F. novicida(Fn)产生具有改变的脂多糖(LPS)结构的减毒菌株,其保护免疫的小鼠免受野生型(WT)Fn的> 25,000 LD 50攻击。我们现在表明,Ft LVS中的类似突变导致脂质A的相同结构修饰,并且在皮下感染C57 BL/6和BALB/c小鼠后在>106 LD 50下是无毒的。 该修订的R21提案的目标是基于Ft LVS(B型)和Ft Schu S4(A型)菌株中lpxF的未标记缺失,开发活的、合理减毒的Ft疫苗。在这两种菌株中工程化未标记的lpxF缺失后,我们将通过质谱法确认来自每个突变体的脂质A的结构,并确认每个突变体确实在小鼠中减毒。此外,我们将测试它们保护WT、IFN-r-/-和TLR 2-/-小鼠免受同源和异源攻击的能力。最后,我们将测试每种突变株诱导与“经典活化”(杀微生物)与“替代活化”(先前显示促进胞质内复制)巨噬细胞相关的巨噬细胞基因表达的能力,以及体外细胞内复制的能力。在本研究完成时,我们预期已开发出一种合理减毒的候选疫苗,可预防多种Ft A型和B型弗朗西斯菌菌株。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert K Ernst其他文献

Robert K Ernst的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert K Ernst', 18)}}的其他基金

Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
假单胞菌脂质 A 结构在 CF 气道疾病进展中的微生物适应
  • 批准号:
    10722599
  • 财政年份:
    2023
  • 资助金额:
    $ 19.19万
  • 项目类别:
Mid-Atlantic Microbial Pathogenesis Meeting 2022
2022 年大西洋中部微生物发病机制会议
  • 批准号:
    10504721
  • 财政年份:
    2022
  • 资助金额:
    $ 19.19万
  • 项目类别:
MS Diagnostic Bacterial Identification Library
MS 诊断细菌鉴定库
  • 批准号:
    10116273
  • 财政年份:
    2020
  • 资助金额:
    $ 19.19万
  • 项目类别:
MS Diagnostic Bacterial Identification Library
MS 诊断细菌鉴定库
  • 批准号:
    10356152
  • 财政年份:
    2020
  • 资助金额:
    $ 19.19万
  • 项目类别:
MS Diagnostic Bacterial Identification Library
MS 诊断细菌鉴定库
  • 批准号:
    10570981
  • 财政年份:
    2020
  • 资助金额:
    $ 19.19万
  • 项目类别:
Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural Variants
基于脂质 A 的结构变体可预防革兰氏阴性脓毒症
  • 批准号:
    9753900
  • 财政年份:
    2016
  • 资助金额:
    $ 19.19万
  • 项目类别:
MS diagnostic bacterial identification library
MS诊断细菌鉴定文库
  • 批准号:
    8722128
  • 财政年份:
    2014
  • 资助金额:
    $ 19.19万
  • 项目类别:
Development of a Rationally Attenuated Live Vaccine for Francisella tularensis
土拉弗朗西斯菌合理减毒活疫苗的研制
  • 批准号:
    8650788
  • 财政年份:
    2013
  • 资助金额:
    $ 19.19万
  • 项目类别:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
修饰脂寡糖和脂质 A 的免疫治疗潜力
  • 批准号:
    8675799
  • 财政年份:
    2013
  • 资助金额:
    $ 19.19万
  • 项目类别:
Immunotherapeutic Potential of Modified Lipooligosaccharides and Lipid A's
修饰脂寡糖和脂质 A 的免疫治疗潜力
  • 批准号:
    8584054
  • 财政年份:
    2013
  • 资助金额:
    $ 19.19万
  • 项目类别:

相似海外基金

AEROSOLS
气雾剂
  • 批准号:
    10101317
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    EU-Funded
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
  • 批准号:
    10092043
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
  • 批准号:
    2332007
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000021/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000358/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
  • 批准号:
    DP240100389
  • 财政年份:
    2024
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
  • 批准号:
    83001507
  • 财政年份:
    2023
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
  • 批准号:
    ST/X001091/1
  • 财政年份:
    2023
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
  • 批准号:
    2326096
  • 财政年份:
    2023
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
  • 批准号:
    10080253
  • 财政年份:
    2023
  • 资助金额:
    $ 19.19万
  • 项目类别:
    Small Business Research Initiative
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了